Weight-loss drug Tirzepatide enters India under Cipla’s new brand ‘Yurpeak’, matches Mounjaro’s pricing

Drugmaker Cipla Limited has announced the launch of a medication, Yurpeak (Tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus, which are two of the country’s most pressing health challenges.

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti-obesity drug brand of Lilly’s Tirzepatide in India, after Lilly received DCGI approval. 

Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with at least one weight-related comorbidity. 

Yurpeak will be available on prescription in the KwikPen device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing. 

Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: “The launch of Yurpeak marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India’s chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitment that define our leadership in chronic diseases and in respiratory care.” 

Cipla says its focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are.

As per the company, the launch of Yurpeak in India will help expand access to Tirzepatide so that more patients can benefit from this innovative therapy. 

Cipla’s strategic priority is to make it available across India, including regions beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater nationwide reach and accessibility. 

Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro. 

Cipla says the launch of Yurpeak will be complemented by comprehensive patient education and support programs, including guidance on dosing, self-administration, and safe, informed use of the therapy. These initiatives help patients navigate treatment confidently and responsibly, in consultation with healthcare professionals, the company said.